Breaking News Instant updates and real-time market news.

BGNE

BeiGene

$135.62

2.61 (1.96%)

19:34
09/22/19
09/22
19:34
09/22/19
19:34

BeiGene announces results on Tislelizumab from ongoing clinical trials

BeiGene announced clinical results on its investigational anti-PD-1 antibody tislelizumab from three ongoing clinical trials in China. This open-label, multi-cohort, Phase 2 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with advanced lung cancer is being conducted in China. Patients with non-squamous non-small cell lung cancer were treated with tislelizumab at a dose of 200mg and doublet chemotherapy on day one of each three-week cycle; chemotherapy was given for up to four cycles, with pemetrexed and tislelizumab continued as scheduled if clinically appropriate. Patients with squamous NSCLC and small cell lung cancer were treated with tislelizumab at a dose of 200mg and doublet chemotherapy every three weeks, for four-six cycles, with tislelizumab continued as scheduled if clinically appropriate. As of February 25, 2019, 54 patients had received tislelizumab, with a median duration of treatment of 38.4 weeks. Fourteen patients remained on treatment as of the data cutoff. Results included the confirmed overall response rate across all cohorts of 66.7%, with ORRs of 43.8% in patients with non-squamous NSCLC; 80.0% in patients with squamous NSCLC; 66.7% in patients with squamous NSCLC; and 76.5% in patients with SCLC; Median progression-free survival was measured at a later data cutoff on June 30, 2019, and was 9.0 months in patients with non-squamous NSCLC, 7.0 months in squamous NSCLC, 6.9 months in SCLC, and in squamous NSCLC the median PFS had not yet been reached; At the median follow-up of 15.3 months, overall survival in patients with SCLC was 15.6 months; OS in other cohorts had not yet been reached; Treatment-emergent adverse events occurred in all 54 patients; adverse events reported as related to tislelizumab occurred in 46 patients, and seven patients discontinued tislelizumab treatment due to AEs; fourteen patients experienced at least one serious TEAE; one patient with squamous NSCLC had a fatal AE of immune-mediated myositis/rhabdomyolysis/cardiomyopathy after one dose of tislelizumab. The open-label, multi-cohort, Phase 2 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with advanced esophageal, gastric or gastroesophageal junction carcinoma is being conducted in China. Patients were treated with tislelizumab at a dose of 200mg and cisplatin on day one, and fluorouracil on days one through five during each 21-day cycle. At the time of data cutoff on March 31, 2019, 15 patients with ESCC had received treatment with tislelizumab, and four remained on treatment. Results included seven patients achieving a confirmed partial response and the ORR was 46.7%; Median duration of response was 12.8 months; median PFS was 10.4 months; Despite a median follow-up of 13.0 months, median OS had not been reached; AEs reported in this cohort were consistent with the safety profile of tislelizumab observed in previous studies with other tumor types and were generally of low severity; AEs reported in this cohort were consistent with the known tolerability profile of PD-1 inhibitors in combination with chemotherapy. The multi-center, open-label Phase 1/2 trial of tislelizumab as monotherapy in patients with advanced solid tumors is being conducted in China and consists of a Phase 1 dose verification and pharmacokinetics component, and a Phase 2 indication expansion in disease-specific cohorts, including patients with non-small cell lung cancer, melanoma, urothelial carcinoma, renal cell carcinoma, esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, and microsatellite instability-high/mismatch repair deficient solid tumors. As of December 1, 2018, 300 patients across all indications had been treated in this study with tislelizumab at a dose of 200mg every three weeks. Tislelizumab was generally well tolerated among patients with advanced solid tumors. One patient with GC experienced a fatal brain edema, which was considered possibly related to tislelizumab treatment by the investigator.

  • 27

    Sep

  • 15

    Oct

  • 27

    Feb

BGNE BeiGene
$135.62

2.61 (1.96%)

06/04/19
BERN
06/04/19
INITIATION
Target $201
BERN
Outperform
BeiGene initiated with an Outperform at Bernstein
Bernstein started BeiGene with an Outperform rating and $201 price target.
06/20/19
PIPR
06/20/19
NO CHANGE
Target $180
PIPR
Overweight
BeiGene gene portfolio development remains on track, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps an Overweight rating on BeiGene with a $180 price after management reviewed recent clinical updates for the zanubrutinib and tislelizumab development programs. The analyst continues to believe that zanubrutinib provides a differentiated therapeutic profile compared to ibrutinib. This will likely prove definitive in the head-to-head Phase III trials to read out later in the year in Waldenstrom macroglobulinemia, Van Buren tells investors in a research note titled "The BeiGene Global Portfolio Development Strategy Remains On Track." Further, the analyst finds the combo's activity in chronic lymphocytic leukemia/small lymphocytic lymphoma and Hodgkin's lymphoma "promising."
07/05/19
MACQ
07/05/19
INITIATION
MACQ
Underperform
BeiGene initiated with an Underperform at Macquarie
09/09/19
PIPR
09/09/19
NO CHANGE
PIPR
BeiGene successfully rebutted short report claims, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says BeiGene management provided a detailed presentation which successfully rebutted the claims made in a short report published last week. The claims being made by the short sellers appear unfounded and management's explanations "were clear and entirely reasonable," Van Buren tells investors in a research note. He points out that BeiGene's Celgene (CELG) product sales are audited by an independent third party and that the * purchase of companies is the typical way to obtain drug distribution licenses in China. The analyst, who continues to have a high level of confidence in BeiGene's management team, keeps an Overweight rating on the shares with a $180 price target.

TODAY'S FREE FLY STORIES

LOGI

Logitech

$40.72

0.66 (1.65%)

21:08
10/21/19
10/21
21:08
10/21/19
21:08
Earnings
Logitech backs FY20 revenue growth outlook in high single digits »

Backs FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

LOGI

Logitech

$40.72

0.66 (1.65%)

21:06
10/21/19
10/21
21:06
10/21/19
21:06
Earnings
Logitech reports Q2 adjusted EPS 50c, consensus 50c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

VG

Vonage

$10.35

-0.04 (-0.38%)

21:05
10/21/19
10/21
21:05
10/21/19
21:05
Hot Stocks
Vonage accelerates expansion into Asia Pacific »

Vonage is continuing its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PG

Procter & Gamble

$119.04

1.55 (1.32%)

, MCD

McDonald's

$209.85

1.365 (0.65%)

20:25
10/21/19
10/21
20:25
10/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$119.04

1.55 (1.32%)

MCD

McDonald's

$209.85

1.365 (0.65%)

UTX

United Technologies

$138.24

1.39 (1.02%)

NEE

NextEra Energy

$232.85

0.17 (0.07%)

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

UPS

UPS

$118.56

1.23 (1.05%)

SHW

Sherwin-Williams

$551.04

-9.93 (-1.77%)

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

BIIB

Biogen

$223.57

3.52 (1.60%)

TRV

Travelers

$141.77

0.33 (0.23%)

PCAR

Paccar

$72.88

0.83 (1.15%)

FITB

Fifth Third

$28.04

0.71 (2.60%)

CNC

Centene

$45.83

-1.09 (-2.32%)

RF

Regions Financial

$16.08

0.305 (1.93%)

NUE

Nucor

$51.78

0.09 (0.17%)

HAS

Hasbro

$120.11

-1.78 (-1.46%)

TRU

TransUnion

$82.55

1.055 (1.29%)

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

IPG

Interpublic Group

$20.79

0.14 (0.68%)

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

PII

Polaris Industries

$91.55

0.935 (1.03%)

SNV

Synovus

$36.30

1.005 (2.85%)

JBLU

JetBlue

$17.54

0.59 (3.48%)

GPK

Graphic Packaging

$14.86

0.205 (1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 07

    Nov

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

OISHY

Oil Search

$0.00

(0.00%)

20:01
10/21/19
10/21
20:01
10/21/19
20:01
Hot Stocks
Oil Search reports Q3 output 6.81MMBOE, down 1% qoq and down 10% yoy »

Cuts FY19 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$95.81

0.63 (0.66%)

19:53
10/21/19
10/21
19:53
10/21/19
19:53
Downgrade
Electronic Arts rating change at Barclays »

Electronic Arts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 13

    Nov

TWTR

Twitter

$40.09

1.11 (2.85%)

, FB

Facebook

$189.82

3.865 (2.08%)

19:48
10/21/19
10/21
19:48
10/21/19
19:48
Hot Stocks
Twitter plans to update rules to address manipulated media on its platform »

The official Twitter…

TWTR

Twitter

$40.09

1.11 (2.85%)

FB

Facebook

$189.82

3.865 (2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 30

    Oct

IRDM

Iridium

$24.23

-0.05 (-0.21%)

19:44
10/21/19
10/21
19:44
10/21/19
19:44
Hot Stocks
Iridium adds Intellian to Certus maritime portfolio »

Iridium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

, NVDA

Nvidia

$196.16

5.69 (2.99%)

19:29
10/21/19
10/21
19:29
10/21/19
19:29
Hot Stocks
Nvidia, Ericsson collaborate on virtualized 5G radio access technology »

NVIDIA (NVDA) and…

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

NVDA

Nvidia

$196.16

5.69 (2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 14

    Nov

  • 20

    Nov

NVDA

Nvidia

$196.16

5.69 (2.99%)

, MSFT

Microsoft

$138.43

1.09 (0.79%)

19:24
10/21/19
10/21
19:24
10/21/19
19:24
Hot Stocks
Nvidia announces technology collaboration with Microsoft »

NVIDIA (NVDA) with…

NVDA

Nvidia

$196.16

5.69 (2.99%)

MSFT

Microsoft

$138.43

1.09 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

19:17
10/21/19
10/21
19:17
10/21/19
19:17
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

U.S. Bancorp will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

ADBE

Adobe

$266.84

1.42 (0.54%)

, AAPL

Apple

$240.49

4.2 (1.78%)

18:55
10/21/19
10/21
18:55
10/21/19
18:55
Periodicals
Adobe to roll out Illustrator app for iPad in 2020, Bloomberg reports »

Adobe (ADBE) has selected…

ADBE

Adobe

$266.84

1.42 (0.54%)

AAPL

Apple

$240.49

4.2 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 23

    Jan

NVDA

Nvidia

$196.16

5.69 (2.99%)

, IBM

IBM

$132.55

-1.55 (-1.16%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Hot Stocks
Nvidia, Red Hat to deliver 5G wireless infrastructure to telecom industry »

Nvidia (NVDA) and Red Hat…

NVDA

Nvidia

$196.16

5.69 (2.99%)

IBM

IBM

$132.55

-1.55 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

  • 14

    Nov

  • 20

    Nov

SMBC

Southern Missouri Bancorp

$36.24

0.38 (1.06%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Earnings
Southern Missouri Bancorp sees Q1 EPS 85c, consensus 78c »

The company announced Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 13

    Nov

CDNS

Cadence Design

$66.67

1.07 (1.63%)

, AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

18:36
10/21/19
10/21
18:36
10/21/19
18:36
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CDNS

Cadence Design

$66.67

1.07 (1.63%)

AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

HLX

Helix Energy

$8.32

0.31 (3.87%)

ZION

Zions Bancorp

$45.68

0.96 (2.15%)

STMP

Stamps.com

$76.12

0.55 (0.73%)

UPS

UPS

$118.56

1.23 (1.05%)

FBP

First BanCorp

$10.24

-0.015 (-0.15%)

VRTX

Vertex

$183.73

7.49 (4.25%)

KDMN

Kadmon

$3.08

0.17 (5.84%)

TACO

Del Taco

$9.66

0.26 (2.77%)

HXL

Hexcel

$74.59

-1.62 (-2.13%)

SITC

Site Centers

$15.27

0.175 (1.16%)

ADC

Agree Realty

$77.01

1.365 (1.80%)

CE

Celanese

$121.37

-0.3 (-0.25%)

HHC

Howard Hughes

$128.38

2.41 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 07

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 19

    Mar

  • 22

    Oct

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

18:31
10/21/19
10/21
18:31
10/21/19
18:31
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

The report cites an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

HLX

Helix Energy

$8.32

0.31 (3.87%)

18:16
10/21/19
10/21
18:16
10/21/19
18:16
Earnings
Helix Energy reports Q3 EPS 21c, consensus 16c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 14

    Nov

CVX

Chevron

$116.66

1.87 (1.63%)

18:07
10/21/19
10/21
18:07
10/21/19
18:07
Periodicals
U.S. Treasury to let Chevron drill in Venezuela for 3 more months, Reuters says »

The U.S. Treasury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, WE

We Company

$0.00

(0.00%)

18:03
10/21/19
10/21
18:03
10/21/19
18:03
Periodicals
SoftBank's WeWork offer would lead to co-founder's exit, Reuters says »

SoftBank (SFTBF) offered…

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$29.51

0.4 (1.37%)

17:59
10/21/19
10/21
17:59
10/21/19
17:59
Earnings
First Defiance Financial reports Q3 EPS 66c, consensus 60c »

Reports Q3 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

UNFI

United Natural Foods

$6.91

0.35 (5.34%)

17:56
10/21/19
10/21
17:56
10/21/19
17:56
Recommendations
United Natural Foods analyst commentary  »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.35

0.135 (0.48%)

17:45
10/21/19
10/21
17:45
10/21/19
17:45
Hot Stocks
Four Corners Property Trust acquires Maryland property for $2M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

RTN

Raytheon

$202.21

2.41 (1.21%)

17:39
10/21/19
10/21
17:39
10/21/19
17:39
Hot Stocks
Raytheon awarded $128.45M Air Force contract for mobile sensors maintenance »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GNTY

Guaranty Bancshares

$30.22

0.02 (0.07%)

17:38
10/21/19
10/21
17:38
10/21/19
17:38
Earnings
Guaranty Bancshares reports Q3 EPS 65c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$45.83

-1.09 (-2.32%)

, WCG

WellCare

$271.41

-3.13 (-1.14%)

17:32
10/21/19
10/21
17:32
10/21/19
17:32
Hot Stocks
Centene announces $500M share repurchase plan »

In a regulatory filing,…

CNC

Centene

$45.83

-1.09 (-2.32%)

WCG

WellCare

$271.41

-3.13 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.